



# A Cost-Effectiveness Analysis of Folic Acid Fortification Policy in the United States

## Citation

Bentley, Tanya GK, Milton C Weinstein, Walter C Willett, and Karen M Kuntz. 2008. "A Cost-Effectiveness Analysis of Folic Acid Fortification Policy in the United States." *Public Health Nutrition* 12 (4): 455. <https://doi.org/10.1017/s1368980008002565>.

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:41426815>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

# A cost-effectiveness analysis of folic acid fortification policy in the United States

Tanya GK Bentley<sup>1,\*†</sup>, Milton C Weinstein<sup>2</sup>, Walter C Willett<sup>3</sup> and Karen M Kuntz<sup>2</sup>

<sup>1</sup>The Faculty of Arts and Sciences, Harvard University Ph.D. Program in Health Policy, 79 John F. Kennedy Street, Cambridge, MA, USA: <sup>2</sup>The Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA: <sup>3</sup>The Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, MA, USA

Submitted 14 May 2007: Accepted 3 April 2008: First published online 1 July 2008

## Abstract

*Objective:* To quantify the health and economic outcomes associated with changes in folic acid consumption following the fortification of enriched grain products in the USA.

*Design:* Cost-effectiveness analysis.

*Setting:* Annual burden of disease, quality-adjusted life years (QALY) and costs were projected for four steady-state strategies: no fortification, or fortifying with 140, 350 or 700 µg folic acid per 100 g enriched grain. The analysis considered four health outcomes: neural tube defects (NTD), myocardial infarctions (MI), colon cancers and B<sub>12</sub> deficiency maskings.

*Subjects:* The US adult population subgroups defined by age, gender and race/ethnicity, with folate intake distributions from the National Health and Nutrition Examination Surveys (1988–1992 and 1999–2000), and reference sources for disease incidence, utility and economic estimates.

*Results:* The greatest benefits from fortification were predicted in MI prevention, with 16 862 and 88 172 cases averted per year in steady state for the 140 and 700 µg fortification levels, respectively. These projections were between 6261 and 38 805 for colon cancer and 182 and 1423 for NTD, while 15–820 additional B<sub>12</sub> cases were predicted. Compared with no fortification, all post-fortification strategies provided QALY gains and cost savings for all subgroups, with predicted population benefits of 266 649 QALY gained and \$3.6 billion saved in the long run by changing the fortification level from 140 µg/100 g enriched grain to 700 µg/100 g.

*Conclusions:* The present study indicates that the health and economic gains of folic acid fortification far outweigh the losses for the US population, and that increasing the level of fortification deserves further consideration to maximise net gains.

## Keywords

Cost-effectiveness analysis  
Folic acid fortification  
Prenatal and maternal nutrition  
Health policy

Increasing the intake of folate or folic acid during preconception and early in pregnancy can significantly reduce the risk of neural tube defects (NTD) in newborns<sup>(1,2)</sup>. Increased intake may also reduce the risk of myocardial infarction (MI) and colon cancer<sup>(3–16)</sup> and increase the risk that symptoms of vitamin B<sub>12</sub> deficiency are masked<sup>(4,5,7,12)</sup>, thereby allowing the neurological manifestations of the disease to progress<sup>(4)</sup>.

In 1998, the US Food and Drug Administration mandated that manufacturers add 140 µg of folic acid per 100 g of enriched cereal-grain product<sup>(11,13,14)</sup>, and several studies have shown that such fortification provides substantial health and economic benefits<sup>(6,8,9,13,14,17–21)</sup>. However, the potential economic and health effects of

this and alternative fortification policies have not been evaluated using national post-policy data adjusted for measurement error, while considering all four relevant health outcomes among population subgroups.

Accordingly, the present analysis quantifies the projected health and economic outcomes for NTD, MI, colon cancers and B<sub>12</sub> maskings associated with the changes in folic acid consumption following fortification in the USA, as well as for alternative fortification levels.

## Methods

### Overview

Population-wide disease burden and the associated costs and quality-adjusted life years (QALY) were projected under four scenarios: no fortification, or fortification with

†Correspondence address: RAND Corporation, 1776 Main Street, PO Box 2138, Santa Monica, CA 90407-2138, USA.

140, 350 or 700  $\mu\text{g}$  of folic acid per 100 g enriched grain. The no-fortification strategy reflects the pre-fortification levels of folate intake, the 140  $\mu\text{g}$  strategy reflects the current post-fortification intake in the USA, and fortifying with 350 and 700  $\mu\text{g}$  are hypothetical scenarios<sup>(13,19,20)</sup>. The four scenarios differ only in terms of the distribution of folate intake in the population, which we model in four categories:  $\leq 200$ , 201–300, 301–400 and  $>400$   $\mu\text{g}/\text{d}$ .

For each scenario, we projected the steady-state number of NTD, MI, colon cancers and B<sub>12</sub> maskings among a US population of non-institutionalised, non-Hispanic white (heretofore referred to as 'white'), non-Hispanic black ('black') and Mexican-American persons aged 15 years or older. Other racial/ethnic subgroups were not included because of insufficient sample size on which to base folate intake estimates. For each folate intake category, we estimated age-, gender- and race/ethnicity-specific risks of developing each of the four health outcomes. We then assigned lifetime QALY losses and disease-related net costs for each health outcome, using either published estimates or a Markov modelling approach, to calculate the population-wide impact of each strategy.

### **Folate intake distributions**

Estimates of population-based folate intake distributions were previously derived using food and dietary supplement data from two periods of the National Health and Nutrition Examination Surveys (NHANES)<sup>(22)</sup>. Briefly, data from NHANES III (1988–1994) were used to estimate pre-fortification food folate intake, and those from NHANES 1999–2000 were used to estimate both dietary supplement intake and post-fortification food folate intake. Because nutrient intake data are based primarily on one 24 h dietary recall measure, which does not represent an individual's average long-term daily intake, population distribution estimates of dietary folate intake were corrected for measurement error using a sub-sample of NHANES III subjects who had provided two 24 h recalls. Total folate intake distributions before and after the fortification policy, corrected for measurement error, are shown in Fig. 1 and in the Appendix. Folate intake for the two hypothetical scenarios was estimated as the product of the pre–post differences in corrected food folate intake and the ratio of the higher to the current levels (e.g. 350/140 for the 350  $\mu\text{g}$  strategy), plus the post-fortification supplement intake.

### **Disease incidence**

Annual incidence of the four disease outcomes prior to fortification was estimated as a function of age range, gender and race/ethnicity (Table 1). When data were not available for the Mexican-American population, the rates for the Hispanic population were used.

All women between the ages of 15 and 44 years<sup>(23–26)</sup> were considered at risk for an NTD-affected pregnancy. NTD incidence as a function of race/ethnicity was based on estimates from the Centers for Disease Control and

Prevention (CDC) of 10.6 cases of spina bifida and anencephaly per 10 000 live births<sup>(9,27)</sup>. Live birth rates from the National Center for Health Statistics<sup>(28)</sup> were used to calculate NTD incidence per 100 000 women aged 15–44 years.

MI incidence was based on calculations by gender and age from the Framingham Risk Equations<sup>(29)</sup>. The relative racial/ethnic distribution of MI incidence was assumed to be the same as that of CHD-specific death among each age and gender-specific subgroup<sup>(30)</sup>. Subgroup-specific annual colon cancer incidence rates were derived from the Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute<sup>(31–33)</sup>.

Vitamin B<sub>12</sub> masking was defined as the delayed diagnosis of B<sub>12</sub> deficiency followed by the development of neurological complications. Estimates of masking risk incorporated the probability of consuming greater than 1000  $\mu\text{g}$  folate/d<sup>(22)</sup> – the 'tolerable upper intake level' for folic acid<sup>(10,11)</sup> – and the risk of pernicious anaemia (PA) – a common cause of B<sub>12</sub> deficiency<sup>(19,34,35)</sup>.


Folate-specific incidence of each disease was calculated by using data on the percentage of the population in each folate intake category (Fig. 1) and the relative risks of disease by folate intake to split out the subgroup-specific disease rates. The risk of NTD was reduced by 50% for women with folate intake levels of greater than 400  $\mu\text{g}/\text{d}$ <sup>(1,2,13,14,19,20)</sup>, and the relative reduction of MI risk for individuals with folate intake greater than 400  $\mu\text{g}/\text{d}$  was 24%<sup>(36)</sup>. The risk ratios for colon cancer diagnosis by folate intake were 0.92, 0.79 and 0.69 for 201–300, 301–400 and  $>400$   $\mu\text{g}/\text{d}$ , respectively, compared with  $\leq 200$   $\mu\text{g}/\text{d}$ <sup>(37)</sup>. Relative risks for MI and colon cancer were assumed to be the same for men and women.

### **Valuing outcomes**

The number of disease events associated with each strategy were estimated as the product of incidence and national population estimates for each subgroup<sup>(38)</sup>. The numbers of events were multiplied by the associated QALY lost and net costs per event (Table 2) to estimate the net health and economic impact of each fortification strategy. All QALY and cost estimates were discounted by 3% per year.

### **Health related quality-of-life**

Estimates of QALY lost for NTD and B<sub>12</sub> masking outcomes were based on a CDC cost-effectiveness analysis<sup>(20)</sup> that used the Quality of Well-Being Index<sup>(39)</sup>. To estimate the QALY lost associated with MI and colon cancer we used a Markov modelling approach in which we incorporated disease-specific mortality, health-related quality-of-life weights and mortality from other causes<sup>(40–42)</sup>. For MI, we assumed the same utility for patients with coronary artery disease (CAD) of 0.84, calculated from previous analyses as the mean of mild and severe angina, weighted by the proportion of angina patients with CAD<sup>(43–45)</sup>. For colon cancer, life expectancy after



**Fig. 1** Daily total folate intake distributions pre- v. -post fortification by gender and race/ethnicity, corrected for measurement error (---◇, pre; —■, post). Reprinted with permission from the American Public Health Association from Bentley TGK, Willett WC, Weinstein WC and Kuntz KM. Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification<sup>(22)</sup>

diagnosis was weighted by stage-specific mortality and we assumed a stage-weighted utility of 0.76<sup>(46)</sup>.

*Costs*

All costs were adjusted to 2005 dollars using the Consumer Price Index. For costs incurred with NTD, estimates from a published analysis<sup>(21)</sup> were used, weighted for relative proportions of spina bifida and anencephaly<sup>(9)</sup>. Costs incurred with MI events incorporated short-term care<sup>(43)</sup> as well as annual outpatient, medications and diagnostic costs for a typical CAD patient<sup>(45,47,48)</sup>, which were

assumed to be applicable to MI patients. Costs incurred with colon cancer incorporated stage-weighted estimates from the Institute of Medicine<sup>(49-56)</sup>, and those associated with cases of masked B<sub>12</sub> deficiency were based on calculations by the CDC<sup>(20)</sup>. Estimates of annual fortification costs for the 140 µg fortification strategy (\$3.3 million) were based on those used by Grosse and colleagues<sup>(21)</sup>, and those for the two hypothetical scenarios (\$6.0 and \$10.6 million for 350 µg and 700 µg fortification strategies, respectively) incorporated the fixed cost estimates from Grosse *et al.* and the CDC's estimates of bulk folic

**Table 1** Estimates of annual disease risk per 100 000 persons\*

	Men			Women		
	Whit†	Black†	Mexican-American	Whit†	Black†	Mexican-American
Neural tube defects						
15–44 years	–	–	–	6.10	4.58	13.31
Myocardial infarctions						
15–44 years	60.6	89.8	23.6	19.1	50.7	6.3
45–64 years	698.3	1100.0	449.7	349.0	918.1	253.3
65+ years	1627.7	2047.7	1306.8	886.3	1363.8	759.4
Colon cancer						
15–44 years	2.98	3.13	1.96	2.21	3.70	1.47
45–64 years	48.51	59.86	24.05	34.53	49.69	20.88
65+ years	247.59	222.24	147.80	199.03	230.91	96.50
Vitamin B <sub>12</sub> masking‡						
15–44 years		0.012			0.029	
45–64 years		0.078			0.185	
65+ years		0.181			0.427	

\*Some age categories have been combined for ease of presentation.

†Non-Hispanic white and non-Hispanic black.

‡Annual rate of vitamin B<sub>12</sub> masking and pernicious anaemia and total folate intake >1000 µg/d.

**Table 2** Net costs incurred and QALY lost associated with NTD, MI, colon cancer and vitamin B<sub>12</sub> masking events\*

Disease outcome	Men	Women	Ranges for sensitivity analyses		Source
			Men	Women	
QALY					
NTD	–	18.91	–	13.0–28.0	Mersereau <i>et al.</i> (2004) <sup>(9)</sup> ; Kelly <i>et al.</i> (1996) <sup>(20)</sup> ; Kaplan <i>et al.</i> (1988) <sup>(39)</sup>
MI	2.12	2.03	1.17–3.07	1.12–2.94	Abby <i>et al.</i> (1998) <sup>(40)</sup> ; Arias (2004) <sup>(41)</sup> ; Thom <i>et al.</i> (2006) <sup>(42)</sup> ; Cohen <i>et al.</i> (2001) <sup>(43)</sup> ; Nease Jr <i>et al.</i> (1995) <sup>(44)</sup> ; Kuntz <i>et al.</i> (1999) <sup>(45)</sup>
CC	2.54	2.96	1.40–3.68	1.63–4.29	Arias (2004) <sup>(41)</sup> ; Ness <i>et al.</i> (1999) <sup>(46)</sup>
B <sub>12</sub>	0.31		0.17–0.45		Kelly <i>et al.</i> (1996) <sup>(20)</sup> ; Kaplan <i>et al.</i> (1988) <sup>(39)</sup>
Costs (thousands of dollars)					
NTD	–	\$185.5	–	\$5.0–\$185.5	Mersereau <i>et al.</i> (2004) <sup>(9)</sup> ; Grosse <i>et al.</i> (2005) <sup>(21)</sup>
MI	\$32.6	\$32.7		\$5.0–\$32.7	Thom <i>et al.</i> (2006) <sup>(42)</sup> ; Cohen <i>et al.</i> (2001) <sup>(43)</sup> ; Kuntz <i>et al.</i> (1999) <sup>(45)</sup> ; Wong <i>et al.</i> (1990) <sup>(47)</sup> ; Stinnett <i>et al.</i> (1996) <sup>(48)</sup>
CC	\$31.8			\$5.0–\$31.8	Frazier <i>et al.</i> (2000) <sup>(49)</sup> ; Khandker <i>et al.</i> (2000) <sup>(50)</sup> ; Loeve <i>et al.</i> (2000) <sup>(51)</sup> ; Ness <i>et al.</i> (2000) <sup>(52)</sup> ; Pignone <i>et al.</i> (2005) <sup>(53)</sup> ; Pignone <i>et al.</i> (2002) <sup>(54)</sup> ; Vijan <i>et al.</i> (2001) <sup>(55)</sup> ; Wagner <i>et al.</i> (1996) <sup>(56)</sup>
B <sub>12</sub>	\$5.3			\$5.0–\$50.0	Kelly <i>et al.</i> (1996) <sup>(20)</sup>

QALY, quality-adjusted life years; NTD, neural tube defects; MI, myocardial infarctions; CC, colon cancer; B<sub>12</sub>, vitamin B<sub>12</sub> masking.

\*Assuming a 3% discount rate.

acid costs, adjusted for cost declines since 1996<sup>(20,21)</sup>. The fortification costs were doubled in sensitivity analysis.

## Results


### Incidence

Figure 2 shows the projected per cent decline in annual disease incidence for NTD, MI and colon cancer, comparing the post-fortification scenarios with pre-fortification.


For NTD-affected pregnancies, average annual incidence for all racial/ethnic groups was predicted to decrease by 5%, 24% and 39% for the 140, 350 and 700 µg/100 g fortification scenarios, respectively. Mexican-Americans were consistently projected to have the largest per cent declines and blacks the lowest. Average annual MI incidence was

predicted to decrease by 2%, 8% and 14% for the lowest-to-highest post-fortification levels, while projected declines of colon cancer were 2%, 11% and 15%. The racial/ethnic subgroups with the greatest predicted benefit were those with the largest post-fortification increases in per cent reaching the risk-reduction folate intake thresholds for each disease outcome. Among older females, for example, whites were estimated to experience the largest increases in per cent consuming greater than 400 µg total folate/d, and were predicted to experience the greatest declines in disease incidence. On the other hand, older black females were predicted to experience a 0–1% increase in MI incidence, due to a decrease in the proportion consuming more than 400 µg/d.

Table 3 shows the projected total annual number of events averted, QALY gained and costs incurred for the



**Fig. 2** (a) Per cent decline in annual incidence of neural tube defects, (b) myocardial infarctions and (c) colon cancers, after folic acid fortification, by age, gender, race/ethnicity and fortification strategy (■, white; ■, black; □, Mexican-American)



**Fig. 2 Continued**

US population. The model predicted that the greatest benefits would be in MI prevention, with 16 862 cases averted per year at the 140 µg fortification level and 88 172 at the highest fortification level. Between 6261 and 38 805 annual cases of colon cancer and 182 and 1423 annual NTD would be prevented, while 15–820 new annual cases of B<sub>12</sub> masking would be caused.

#### **Quality-of-life and cost measures**

Fortification was predicted to be cost-saving and to provide positive net QALY gains at all fortification levels, and

the 700 µg/100 g strategy was projected to have the largest health gain and cost savings, with over 320 000 QALY gained and over \$4 billion saved per year (Table 3). The predicted annual gains of over 26 000 QALY and savings of over \$263 million from NTD prevention alone far outweighed the QALY lost and costs incurred from B<sub>12</sub> masking and fortification itself, which combined were predicted to result in annual losses of fewer than 260 QALY and \$15 million even at the highest fortification level. QALY gains and cost savings due to MI and colon cancers averted each year would be even greater, with MI

**Table 3** Annual QALY and costs associated with US folic acid fortification, by fortification strategy and outcome

Strategy*	NTD	MI	CC	B <sub>12</sub>	Net	
Events averted						
140 µg/100 g	182	16 862	6261	-15	23 289	
350 µg/100 g	883	53 011	20 110	-184	73 821	
700 µg/100 g	1423	88 172	38 805	-820	127 579	
QALY gained						
140 µg/100 g	3436	35 458	17 402	-5	56 291	
350 µg/100 g	16 697	111 121	57 403	-57	185 165	
700 µg/100 g	26 899	184 149	112 146	-254	322 940	
Costs incurred (millions of dollars)†					Fortification costs	Net costs
140 µg/100 g	-\$33.7	-\$550.8	-\$199.4	\$0.1	\$3.3	-\$780.5
350 µg/100 g	-\$163.8	-\$1731.5	-\$640.4	\$1.0	\$6.0	-\$2528.8
700 µg/100 g	-\$263.9	-\$2880.0	-\$1235.7	\$4.3	\$10.5	-\$4364.8

QALY, quality-adjusted life years; NTD, neural tube defects; MI, myocardial infarctions; CC, colon cancer; B<sub>12</sub>, vitamin B<sub>12</sub> masking.

\*Strategies labelled by amount of fortification in µg of folic acid added per 100 g of enriched grain product.

†Disease-specific costs do not include fortification costs.

**Table 4** Annual QALY and costs (millions of dollars) associated with US folic acid fortification, by gender, age and race/ethnicity

Strategy*	Non-Hispanic white		Non-Hispanic black		Mexican-American	
	QALY	Costs	QALY	Costs	QALY	Costs
Men aged 15–44 years						
140 µg/100 g	3041	-\$45.23	506	-\$7.50	265	-\$3.86
350 µg/100 g	7241	-\$108.51	1849	-\$27.84	551	-\$8.11
700 µg/100 g	9078	-\$135.52	2996	-\$45.19	600	-\$8.72
Men aged 45–64 years						
140 µg/100 g	12 939	-\$194.42	2336	-\$35.05	642	-\$9.65
350 µg/100 g	31 967	-\$482.75	6846	-\$103.34	1700	-\$25.68
700 µg/100 g	41 703	-\$630.77	10 745	-\$162.67	2358	-\$35.68
Men aged 65+ years						
140 µg/100 g	13 204	-\$190.82	1663	-\$24.61	334	-\$4.94
350 µg/100 g	38 477	-\$569.02	3394	-\$50.56	860	-\$12.79
700 µg/100 g	59 677	-\$888.08	5129	-\$76.52	1483	-\$22.15
Women aged 15–44 years						
140 µg/100 g	2627	-\$27.21	532	-\$6.18	1068	-\$10.17
350 µg/100 g	13 404	-\$141.13	1923	-\$22.68	4426	-\$43.23
700 µg/100 g	22 210	-\$233.64	3722	-\$43.99	5964	-\$57.89
Women aged 45–64 years						
140 µg/100 g	5335	-\$78.24	802	-\$11.60	113	-\$1.61
350 µg/100 g	16 605	-\$251.04	3998	-\$60.75	412	-\$6.10
700 µg/100 g	24 415	-\$372.64	10 916	-\$169.90	1017	-\$15.45
Women aged 65+ years						
140 µg/100 g	6295	-\$79.78	87	-\$0.38	48	-\$0.58
350 µg/100 g	18 833	-\$262.02	192	-\$1.52	95	-\$1.26
700 µg/100 g	42 384	-\$618.09	924	-\$9.45	279	-\$3.86

QALY, quality-adjusted life years.

\*Strategies labelled by amount of fortification in µg of folic acid added per 100 g of enriched grain product.

prevention alone predicted to save 184 000 QALY and \$3 billion annually at the 700 µg level.

The model predicted the 700 µg fortification level to yield the greatest net QALY gains and cost savings for all age, gender and racial/ethnic subgroups (Table 4). Benefits were projected to increase with age, with males predicted to benefit more than females in most populations. At all fortification levels, the highest gains were expected in white males aged 65 years and older, with predicted annual gains of over 13 000 QALY and \$190 million at the currently enacted level and over 59 000 QALY and \$888 million at the 700 µg level. Among racial/ethnic categories, whites were projected to experience the greatest gains and Mexican-Americans the fewest.

**Sensitivity analyses**


This analysis projected substantial fortification benefits despite predicting at the currently enacted fortification level a 5% reduction in NTD rates, which is far less than the 20–30% declines estimated from observed data<sup>(6,8,9,17)</sup>. Due to lack of adequate dose–response data, the model allows only for reduced NTD risk at folate consumption of >400 µg/d, yet there may be benefits in NTD risk-reduction at lower levels.

To evaluate the effect of this possibility, three additional NTD dose–response assumptions were tested (Fig. 3a), allowing women to benefit from folate intake over 200 µg/d<sup>(57–60)</sup>. Curve A assumes a dose–response gradient similar to that of colon cancer – albeit through different



mechanisms – while B and C were calculated by decreasing the risk ratios of function A by 25% and 50%, respectively. All three functions maintained the base-case assumption of a 50% reduced risk for intake  $>400 \mu\text{g}/\text{d}$  compared with  $\leq 400 \mu\text{g}/\text{d}$ . Given the use of a similar  $400 \mu\text{g}/\text{d}$  threshold for reducing the risk of MI by folate intake and evidence of potential benefit at lower levels without a threshold effect<sup>(61)</sup>, an analogous sensitivity analysis on this dose–response function was performed (Fig. 3b).

When risk reduction benefits for NTD and MI were allowed at lower folate intakes, the model predicted that



**Fig. 3** Dose–response assumptions used in sensitivity analyses for (a) neural tube defects (NTD) and (b) myocardial infarctions (MI). Risk is relative to an average folate intake of  $<200 \mu\text{g}$  per day (—, base case; ----, A; ·····, B; - · - ·, C)

more events would be prevented and there would be greater reductions in disease incidence. The use of NTD function B predicted at the  $140 \mu\text{g}$  level a 23% risk reduction, the closest approximation to observed data. When applying these functions for both NTD and MI dose–response, the  $700 \mu\text{g}$  strategy was predicted to save 370 000 QALY and \$5 billion, compared with 320 000 QALY and \$4 billion in the base case (Table 5).

To evaluate the effect of the model's other assumptions, a range of estimates were applied for QALY and costs (Table 2), relative risk of NTD-affected pregnancy (10% and 90%), masking risk (30–200% of base case), female PA risk (150% of base case)<sup>(34,35,62)</sup>, and discount rate (0% and 5%). Even with extreme estimates that would bias results away from fortification, none of these variations – applied individually or concurrently – changed the rankings between strategies or the conclusion that QALY gains and cost savings would result from fortification up to the highest level considered. When biasing against fortification overall, the conclusions remained the same, even though the predicted QALY gained and costs saved were smaller: for all subgroups, fortification would remain cost saving, and the  $700 \mu\text{g}$  strategy would provide the greatest total QALY gains, with \$486 million saved and over 196 000 QALY gained.

## Discussion

It was predicted for three post-fortification strategies that the projected health and economic benefits gained from preventing NTD, MI and colon cancers in the US population far exceeded those lost due to fortification itself and increased  $\text{B}_{12}$  masking risk, with significant variations by age, gender and race/ethnicity. For all health outcomes, the QALY and cost benefits to whites were projected to be significantly greater than those to blacks and Mexican-Americans. With predicted population benefits of 322 940 QALY gained and \$4.4 billion saved, fortifying at  $700 \mu\text{g}/100 \text{g}$  enriched grain product – the highest level considered in this analysis – strongly dominated all other scenarios. The benefits of higher fortification levels were predicted to far outweigh the associated risks for all populations, and in all sensitivity analyses.

**Table 5** QALY and costs (millions of dollars) associated with folic acid fortification, using alternative NTD and MI dose–response functions\*

Strategy†	Annual QALY gains					Annual net costs
	NTD	MI	CC	$\text{B}_{12}$	Net QALY gain	
No fortification	0	0	0	0	0	\$0
$140 \mu\text{g}/100 \text{g}$	15 842	114 532	17 402	–5	147 770	–\$2154
$350 \mu\text{g}/100 \text{g}$	28 445	193 475	57 403	–57	279 267	–\$3958
$700 \mu\text{g}/100 \text{g}$	33 268	224 325	112 146	–254	369 485	–\$5078

QALY, quality-adjusted life years; NTD, neural tube defects; MI, myocardial infarctions; CC, colon cancer;  $\text{B}_{12}$ , vitamin  $\text{B}_{12}$  masking.

\*NTD dose–response function assumes the following relative risks of NTD-affected pregnancy: 0.36; 0.50 and 0.65 for maternal folate intake of  $>400$ , 301–400 and 201–300  $\mu\text{g}/\text{d}$ , respectively, compared to  $\leq 200 \mu\text{g}/\text{d}$ . MI dose–response function assumes the following relative risks of MI: 0.59; 0.63 and 0.70 for folate intake of  $>400$ , 301–400 and 201–300  $\mu\text{g}/\text{d}$ , respectively, compared to  $\leq 200 \mu\text{g}/\text{d}$ .

†Strategies labelled by amount of fortification in  $\mu\text{g}$  of folic acid added per 100 g of enriched grain product.

The substantial racial/ethnic differences predicted in disease outcomes were caused primarily by differences in total folate intake. Although disease incidence was not projected to decrease among all populations, this effect was caused by the unrealistic discontinuous risk functions used to avoid interpolating the epidemiological data analysed in risk strata. Targeted supplement-use interventions may be necessary to further mitigate disparities and reduce disease prevalence, and future research should aim to identify racial/ethnic differences in intake of fortified and non-fortified foods.

The results of the present analysis provide evidence for recommending that fortification be increased to at least 700 µg of folic acid per 100 g of enriched grain product, corroborating prior research that predicted greater economic gains at higher fortification levels<sup>(20)</sup>. The analysis demonstrates that the benefits of higher fortification would exceed the risks even in the most unfavourable subgroups. It also addresses other important considerations by using estimates of folate intake that are national, subgroup-specific, and corrected for the bias caused by the use of 1 d dietary intake data.

There are several limitations to consider when interpreting these results. The use of limited data on the dose–response relationships between folate intake and disease risk may have underestimated the post-fortification health benefits. However, even when using more realistically continuous – albeit uncertain – dose–response assumptions for both NTD and MI, the conclusions of positive benefit–risk trade-offs for all subgroups – and of greater benefit at higher fortification levels – did not change, and the model predicted that more NTD and MI would be prevented and that the NTD reduction would be consistent with that observed post-policy<sup>(6,8,9,17)</sup>.

A related source of uncertainty is that synthetic folic acid is more bioavailable to absorption by the human body than is naturally occurring folate. While this factor can be incorporated using dietary folate equivalents (DFE) – a measure that adjusts intake estimates for these absorption differences – we were unable to include DFE in our analysis due to data limitations. With fortification resulting in greater proportions of intake from synthetic folic acid, the model's use of total folate may thus have caused the benefits of fortification to be underestimated, and the risks to be overestimated. Conversely, because this factor was not considered in estimating folate-specific risks of MI and colon cancer, the benefits for dietary sources of folate may be overstated. The model's projected cost savings associated with fortification may have been underestimated, as lifetime caregiving costs of NTD-affected individuals were not included, reduced costs associated with the proportion of NTD ending in a terminated pregnancy were excluded, and MI costs were used that may not consider the increased costs of today's standards of care. By the same token, we may have overestimated QALY losses due to MI because survival

has been improved by today's standards of care. Taken as a whole, it is unlikely that any such positive or negative effects would substantially impact the results of the analysis, or alter the conclusions of overall benefit.

Given the suggestion of possible insignificant or even adverse effects of increased folate intake on MI risk and on colorectal cancer progression among individuals with pre-existing disease<sup>(3,63–67)</sup>, the benefits to MI as well as to colon cancer could be less than predicted by our model. However, recent evidence also indicates a positive folate–stroke association<sup>(68–70)</sup> and an overall cardiovascular benefit<sup>(16)</sup>, and our results may thus underestimate benefits. The potential risk to colorectal cancer progression may appear to be supported by recent published research indicating a possible temporary delay in the ongoing decline in colorectal cancer incidence<sup>(71)</sup>, but this could be in part an artefact of increased use of colonoscopy. In addition, a recent report from the National Cancer Institute indicates that not only is incidence still decreasing at 2% per year, but also mortality – which one would expect to increase if fortification were accelerating growth of existing tumours – is also declining at an annual rate of close to 4%<sup>(72)</sup>. This analysis is thus important for motivating further trials among people without existing disease, while simultaneously suggesting caution among policymakers who may be considering potential fortification increases.

By not formally allowing competing risks between disease outcomes while allocating benefit for each disease event averted, the model may have double-counted some of the benefits gained because multiple events may be occurring per individual. The analysis did not incorporate potential associations of folic acid intake with increased twinning<sup>(73–76)</sup>, with other cancers<sup>(77–79)</sup>, or with cognitive decline<sup>(80)</sup>. Given the lack of consistent evidence for such outcomes, it is unclear in which direction their inclusion may impact results, yet the strength of the findings from our analysis suggests that the conclusion of overall benefit associated with increased folate intake would not be changed.

While these benefit–risk estimates assume a steady state, in reality fortification's effect on NTD and B<sub>12</sub> maskings would be relatively immediate, while that for MI and colon cancer could take up to 5<sup>(36)</sup> and 15 years<sup>(37)</sup>, respectively. However, not only were fortification's benefits for NTD alone predicted to outweigh the potential B<sub>12</sub> masking risk, this risk may in fact have been overestimated given our use of a conservative risk threshold of 1000 µg/d despite no evidence of harm below 5000 µg/d<sup>(10)</sup>. It is also important to note that while there is conflicting evidence regarding whether masking has increased since fortification<sup>(81–83)</sup>, current medical knowledge regarding appropriate screening measures for B<sub>12</sub> deficiency suggests that the fear of delayed diagnosis by physicians may not in fact be realised. The risk, however, may be that symptom improvement due to

masking could reduce patients' likelihood of seeking medical advice until after neurological complications have occurred<sup>(84)</sup>. Nevertheless, with the low prevalence of potential masking – estimated at 0.09% in older women before fortification and 0.61% after<sup>(83)</sup> – even with conservative estimates our model predicted that this risk would be outweighed by the benefits.

Given the uncertainty involved, future research should clarify the dose–response relationships and benefit–risk associations between folate intake and disease risk. This is especially important for outcomes such as MI, colon cancer, stroke, cognitive decline and B<sub>12</sub> masking, for which causality has not yet been established; there has been conflicting evidence on potential risks, in particular among individuals with pre-existing disease; or there remains debate over the validity of the evidence<sup>(3,16,67–70,81–88)</sup>. In addition, future policy decisions may consider B<sub>12</sub> co-fortification or a more stringent screen for B<sub>12</sub> deficiency to offset the potentially elevated B<sub>12</sub> masking risks due to higher fortification, and may evaluate a broader range of fortification levels to better determine the optimal fortification strategy.

In summary, folic acid fortification was implemented in the USA in 1998 to reduce the chance of NTD in newborns. While there are potential risks of increased folate intake to populations with vitamin B<sub>12</sub> deficiency, there may also be benefits in preventing MI and colon cancer. Overall, in considering the benefit–risk trade-offs of folic acid fortification, the present study suggests that the health and economic gains may outweigh the losses for the US population as a whole, and that additional studies on the potential benefits and hazards associated with folate intake – as well as an in-depth evaluation of the level of fortification – deserve further consideration in order to maximise net gains among all racial/ethnic, age and gender-specific subgroups.

## Acknowledgements

*Conflict of interest:* There are no conflicts of interest.

*Funding source:* This study was supported by the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training, National Cancer Institute training grant # R25 CA92203, and by CISNET, National Cancer Institute grant # UOI CA88204. The work of all authors is independent of these funders.

*Authorship responsibilities:* All authors were involved in the study design and concept. K.M.K. and T.G.K.B. obtained funding. T.G.K.B. acquired all data, drafted the manuscript, and conducted all analyses. K.M.K. supervised study implementation. All authors were involved in interpretation of data and analyses, offered critical revisions to the manuscript, and approved the final version. T.G.K.B. is the guarantor. Ethical approval was not required for this analysis.

## References

1. Czeizel AE & Dudas I (1992) Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* **327**, 1832–1835.
2. MRC Vitamin Study Research Group (1991) Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. *Lancet* **338**, 131–137.
3. Bazzano LA, Reynolds K, Holder KN & He J (2006) Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA* **296**, 2720–2726.
4. Bentley JR, Ferrini RL & Hill LL (1999) American College of Preventive Medicine public policy statement. Folic acid fortification of grain products in the US to prevent neural tube defects. *Am J Prev Med* **16**, 264–267.
5. Dickinson CJ (1995) Does folic acid harm people with vitamin B<sub>12</sub> deficiency? *QJM* **88**, 357–364.
6. Erickson JD (2002) Folic acid and prevention of spina bifida and anencephaly. *MMWR Recomm Rep* **51**, 1–3.
7. Koehler KM, Pareo-Tubbeh SL, Romero LJ, Baumgartner RN & Garry PJ (1997) Folate nutrition and older adults: challenges and opportunities. *J Am Diet Assoc* **97**, 167–173.
8. Mathews TJ, Honein MA & Erickson JD (2002) Spina bifida and anencephaly prevalence – United States, 1991–2001. *MMWR Recomm Rep* **51**, 9–11.
9. Centers for Disease Control and Prevention (CDC) (2004) Spina bifida and anencephaly before and after folic acid mandate – United States, 1995–1996 and 1999–2000. *MMWR Morb Mortal Wkly Rep* **53**, 362–365.
10. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board (1998) *Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Pantothenic acid, Biotin, and Choline*. Washington, DC: National Academy Press.
11. National Institutes of Health Clinical Nutrition Service (2001) Facts about dietary supplements: folate. <http://ods.od.nih.gov/factsheets/cc/folate.html> (accessed November 2004).
12. Tucker KL, Mahnken B, Wilson PW, Jacques P & Selhub J (1996) Folic acid fortification of the food supply. Potential benefits and risks for the elderly population [comment]. *JAMA* **276**, 1879–1885.
13. US Food and Drug Administration (1993) Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. *Fed Regist* **58**, 53305–53312.
14. US Food and Drug Administration (1996) Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. *Fed Regist* **61**, 8781–8797.
15. US Food and Drug Administration (1996) Folic acid fortification fact sheet. <http://vm.dfsan.fda.gov/~dms/wh-folic.html> (accessed April 2003).
16. Wald DS, Wald NJ, Morris JK & Law M (2006) Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *BMJ* **333**, 1114–1117.
17. Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, Sever LE, Miller LA, Meaney FJ & Levitt M (2002) Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. *Teratology* **66**, 33–39.
18. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L & Goldman L (2001) Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. *JAMA* **286**, 936–943.

19. Romano PS, Waitzman NJ, Scheffler RM & Pi RD (1995) Folic acid fortification of grain: an economic analysis. *Am J Public Health* **85**, 667–676.
20. Kelly A, Haddix A, Scanlon K, Helmick C & Mulinare J (1996) Worked example: cost-effectiveness of strategies to prevent neural tube defects. In *Cost-effectiveness in Health and Medicine*, pp. 313–348 [M Gold, J Siegel, L Russell and M Weinstein, editors]. New York: Oxford University Press.
21. Grosse SD, Waitzman NJ, Romano PS & Mulinare J (2005) Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. *Am J Public Health* **95**, 1917–1922.
22. Bentley TGK, Willett WC, Weinstein MC & Kuntz KM (2006) Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. *Am J Public Health* **96**, 2040–2047.
23. Centers for Disease Control and Prevention (2000) Folate status in women of childbearing age – United States, 1999. *MMWR Morb Mortal Wkly Rep* **49**, 962–965.
24. Johnston R & Staples D (1997) Knowledge and use of folic acid by women of childbearing age – United States, 1997. *MMWR Recomm Rep* **46**, 721–723.
25. Centers for Disease Control and Prevention (CDC) (2002) Folate status in women of childbearing age, by race/ethnicity – United States, 1999–2000. *MMWR Morb Mortal Wkly Rep* **51**, 808–810.
26. Petrini J, Damus K, Johnston R & Mattison D (1999) Knowledge and use of folic acid by women of childbearing age – United States, 1995 and 1998. *MMWR Recomm Rep* **48**, 325–327.
27. Williams L, Rasmussen SA, Flores A, Kirby R & Edmonds LD (2005) Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995–2002. *Pediatrics* **116**, 580–586.
28. Hamilton B, Sutton P & Ventura S (2003) Revised birth and fertility rates for the 1990s and new rates for Hispanic populations, 2000 and 2001: United States. *Natl Vital Stat Rep* **51**.
29. Anderson KM, Odell PM, Wilson PW & Kannel WB (1991) Cardiovascular disease risk profiles. *Am Heart J* **121**, 293–298.
30. Centers for Disease Control and Prevention (2006) Health data for all ages – adult mortality by cause: US/State, 1999–2002. [http://www.cdc.gov/nchs/health\\_data\\_for\\_all\\_ages.htm](http://www.cdc.gov/nchs/health_data_for_all_ages.htm) (accessed October 2006).
31. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch (1999) Surveillance, Epidemiology, and End Results (SEER) Program SEER\*Stat Database: Incidence – SEER 11 Regs Public-Use, Aug 1999 Sub for Hispanics (1992–1997). [www.seer.cancer.gov](http://www.seer.cancer.gov) (accessed February 2005).
32. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L & Edwards BK (editors) (2002) *SEER Cancer Statistics Review, 1973–1999*. Bethesda, MD: National Cancer Institute; available at [http://seer.cancer.gov/csr/1973\\_1999/](http://seer.cancer.gov/csr/1973_1999/)
33. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ & Edwards BK (editors) (2004) *SEER Cancer Statistics Review, 1975–2001*. Bethesda, MD: National Cancer Institute; available at [http://seer.cancer.gov/csr/1975\\_2001/](http://seer.cancer.gov/csr/1975_2001/)
34. Borch K & Liedberg G (1984) Prevalence and incidence of pernicious anemia. An evaluation for gastric screening. *Scand J Gastroenterol* **19**, 154–160.
35. Pedersen AB & Mosbech J (1969) Morbidity of pernicious anaemia. Incidence, prevalence, and treatment in a Danish county. *Acta Med Scand* **185**, 449–452.
36. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C & Stampfer MJ (1998) Folate and vitamin B<sub>6</sub> from diet and supplements in relation to risk of coronary heart disease among women. *JAMA* **279**, 359–364.
37. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE & Willett WC (1998) Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. *Ann Intern Med* **129**, 517–524.
38. US Census Bureau, Population Division (2005) Annual Population Estimates. <http://www.census.gov/popest/national/> (accessed July 2005).
39. Kaplan RM & Anderson JP (1988) A general health policy model: update and applications. *Health Serv Res* **23**, 203–235.
40. Abby SL, Harris IM & Harris KM (1998) Homocysteine and cardiovascular disease. *J Am Board Fam Pract* **11**, 391–398.
41. Arias E (2004) United States life tables, 2001. *Natl Vital Stat Rep* **52**.
42. Thom T, Haase N, Rosamond W *et al.* (2006) Heart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* **113**, e85–e151.
43. Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW & Grines CL (2001) Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial. *Circulation* **104**, 3039–3045.
44. Nease RF Jr, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, Pryor D & Sox HC (1995) Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. *JAMA* **273**, 1185–1190.
45. Kuntz KM, Fleischmann KE, Hunink MGM & Douglas PS (1999) Cost-effectiveness of diagnostic strategies for patients with chest pain. *Ann Intern Med* **130**, 709–718.
46. Ness RM, Holmes AM, Klein R & Dittus R (1999) Utility valuations for outcome states of colorectal cancer. *Am J Gastroenterol* **94**, 1650–1657.
47. Wong JB, Sonnenberg FA, Salem DN & Pauker SG (1990) Myocardial revascularization for chronic stable angina. *Ann Intern Med* **113**, 852.
48. Stinnett A, Mittleman M, Weinstein M *et al.* (1996) Appendix C: the cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In *Cost-Effectiveness in Health and Medicine*, pp. 349–391 [M Gold, J Siegel, L Russell and M Weinstein, editors]. New York: Oxford University Press.
49. Frazier AL, Colditz GA, Fuchs CS & Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. *JAMA* **284**, 1954–1961.
50. Khandker RK, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB & Baine WB (2000) A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. *Int J Technol Assess Health Care* **16**, 799–810.
51. Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ & Habbema JD (2000) Endoscopic colorectal cancer screening: a cost-saving analysis. *J Natl Cancer Inst* **92**, 557–563.
52. Ness RM, Holmes AM, Klein R & Dittus R (2000) Cost-utility of one-time colonoscopic screening for colorectal cancer at various ages. *Am J Gastroenterol* **95**, 1800–1811.
53. Pignone M, Russell L & Wagner J (editors) (2005) *Economic Models of Colorectal Cancer Screening in Average-risk Adults: Workshop Summary*. London: Institute of Medicine, National Academies Press.
54. Pignone M, Saha S, Hoerger T & Mandelblatt J (2002) Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. *Ann Intern Med* **137**, 96–104.

55. Vijan S, Hwang EW, Hofer TP & Hayward RA (2001) Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. *Am J Med* **111**, 593–601.
56. Wagner J, Tunis S, Brown M, Ching A & Almeida R (1996) Cost-effectiveness of colorectal cancer screening in average-risk adults. In *Prevention and Early Detection of Colorectal Cancer*, pp. 321–356. [G Young, P Rozen and B Levin, editors]. London: Saunders.
57. Werler M, Shapiro S & Mitchell A (1993) Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA* **269**, 1257–1261.
58. Daly LE, Kirke PN, Molloy A, Weir DG & Scott JM (1995) Folate levels and neural tube defects. Implications for prevention [comment]. *JAMA* **274**, 1698–1702.
59. Daly S, Mills JL, Molloy AM, Conley M, Lee YJ, Kirke PN, Weir DG & Scott JM (1997) Minimum effective dose of folic acid for food fortification to prevent neural-tube defects. *Lancet* **350**, 1666–1669.
60. Wald NJ, Law MR, Morris JK & Wald DS (2001) Quantifying the effect of folic acid. *Lancet* **358**, 2069–2073.
61. Drogan D, Klipstein-Grobusch K, Dierkes J, Weikert C & Boeing H (2006) Dietary intake of folate equivalents and risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition (EPIC)—Potsdam study. *Public Health Nutr* **9**, 465–471.
62. Carmel R (1996) Prevalence of undiagnosed pernicious anemia in the elderly. *Arch Intern Med* **156**, 1097–1100.
63. Novakovic P, Stempak JM, Sohn KJ & Kim YI (2006) Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. *Carcinogenesis* **27**, 916–924.
64. Cole BF, Baron JA, Sandler RS *et al.*; Polyp Prevention Study Group (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. *JAMA* **297**, 2351–2359.
65. Van Guelpen B, Hultdin J, Johansson I, Hallmans G, Stenling R, Riboli E, Winkvist A & Palmqvist R (2006) Low folate levels may protect against colorectal cancer. *Gut* **55**, 1461–1466.
66. Lonn E, Yusuf S, Arnold MJ *et al.*; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* **354**, 1567–1577.
67. Bona KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E & Rasmussen K; NORVIT Trial Investigators (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med* **354**, 1578–1588.
68. Carlsson CM (2007) Lowering homocysteine for stroke prevention. *Lancet* **369**, 1841–1842.
69. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L & Xu X (2007) Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet* **369**, 1876–1882.
70. Toole J, Malinow M, Chambless L, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH & Stampfer M (2004) Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. *JAMA* **291**, 565–575.
71. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G & Rosenberg IH (2007) A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. *Cancer Epidemiol Biomarkers Prev* **16**, 1325–1329.
72. Ries LAG, Melbert D, Krapcho M *et al.* (editors) (2007) *SEER Cancer Statistics Review, 1975–2004*. Bethesda, MD: National Cancer Institute; available at [http://seer.cancer.gov/csr/1975\\_2004/](http://seer.cancer.gov/csr/1975_2004/)
73. Czeizel AE, Metneki J & Dudas I (1994) The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes. *Acta Genet Med Gemellol (Roma)* **43**, 175–184.
74. Li Z, Gindler J, Wang H, Berry RJ, Li S, Correa A, Zheng JC, Erickson JD & Wang Y (2003) Folic acid supplements during early pregnancy and likelihood of multiple births: a population-based cohort study. *Lancet* **361**, 380–384.
75. Lawrence JM, Watkins ML, Chiu V, Erickson JD, Petitti DB & Kim YI (2004) Food fortification with folic acid and rate of multiple births, 1994–2000. *Birth Defects Res A Clin Mol Teratol* **70**, 948–952.
76. Kucik J & Correa A (2004) Trends in twinning rates in metropolitan Atlanta before and after folic acid fortification. *J Reprod Med* **49**, 707–712.
77. Kim YI (2004) Will mandatory folic acid fortification prevent or promote cancer? *Am J Clin Nutr* **80**, 1123–1128.
78. Hena O, Piyathilake C, Waterbor J, Funkhouser E, Johanning GL, Heimburger DC & Partridge EE (2005) Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. *Int J Cancer* **113**, 991–997.
79. Larsson S, Giovannucci E & Wolk A (2007) Folate and risk of breast cancer: a meta-analysis. *J Natl Cancer Inst* **99**, 64–76.
80. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB & Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet* **369**, 208–216.
81. Mills JL, Von Kohorn I, Conley MR, Zeller JA, Cox C, Williamson RE & Dufour DR (2003) Low vitamin B-12 concentrations in patients without anemia: the effect of folic acid fortification of grain. *Am J Clin Nutr* **77**, 1474–1477.
82. Morris MS, Jacques PF, Rosenberg IH & Selhub J (2007) Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. *Am J Clin Nutr* **85**, 193–200.
83. Ray JG, Vermeulen MJ, Langman LJ, Boss SC & Cole DE (2003) Persistence of vitamin B<sub>12</sub> insufficiency among elderly women after folic acid food fortification. *Clin Biochem* **36**, 387–391.
84. Brouwer I & Verhoef P (2007) Folic acid fortification: is masking of vitamin B-12 deficiency what we should really worry about? *Am J Clin Nutr* **86**, 897–898.
85. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW & van Veldhuisen DJ (2003) Secondary prevention with folic acid: effects on clinical outcomes. *J Am Coll Cardiol* **41**, 2105–2113.
86. The Heart Outcomes Prevention Evaluation Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med* **354**, 1567–1577.
87. Wyckoff KF & Ganji V (2007) Proportion of individuals with low serum vitamin B-12 concentrations without macrocytosis is higher in the post folic acid fortification period than in the pre folic acid fortification period. *Am J Clin Nutr* **86**, 1187–1192.
88. Powers HJ (2007) Folic acid under scrutiny. *Br J Nutr* **98**, 665–666.

**Appendix: Population total folate consumption by age, gender, race/ethnicity and folic acid fortification level**

	Folate intake*															
	No fortification				140 µg/100g†				350 µg/100g				700 µg/100g			
	≤200	201–300	301–400	>400	≤200	201–300	301–400	>400	≤200	201–300	301–400	>400	≤200	201–300	301–400	>400
<b>Males</b>																
Non-Hispanic white (%)																
15–44 years	19	28	17	36	0	17	23	57	0	3	11	86	0	0	1	99
45–64 years	13	21	14	52	3	13	18	66	0	3	9	88	0	0	1	99
65+ years	17	23	15	45	4	19	21	55	0	5	17	78	0	0	1	99
Non-Hispanic black (%)																
15–44 years	26	46	14	14	5	35	33	27	0	8	28	64	0	0	4	96
45–64 years	41	24	12	23	15	27	21	38	2	11	19	68	0	1	5	94
65+ years	49	23	10	19	35	20	12	32	26	16	12	46	19	12	10	59
Mexican-American (%)																
15–44 years	27	35	17	21	2	17	27	54	0	1	6	93	0	0	0	100
45–64 years	25	29	16	29	6	23	24	47	0	5	16	78	0	0	2	98
65+ years	26	28	16	30	13	25	21	41	3	16	20	60	0	4	11	84
<b>Females</b>																
Non-Hispanic white (%)																
15–44 years	41	23	5	31	9	32	20	39	0	7	22	71	0	0	1	99
45–64 years	28	19	8	46	7	21	16	56	0	5	14	80	0	0	1	98
65+ years	23	21	8	48	8	25	15	52	0	11	24	65	0	0	5	95
Non-Hispanic black (%)																
15–44 years	60	18	4	18	31	29	14	26	10	22	20	48	2	8	13	76
45–64 years	52	19	5	24	24	34	14	28	3	23	29	46	0	1	11	88
65+ years	53	23	7	17	41	35	7	16	11	65	7	16	0	23	61	16
Mexican-American (%)																
15–44 years	63	21	4	12	12	35	25	28	0	6	18	77	0	0	1	99
45–64 years	44	21	6	29	25	29	13	33	8	25	22	45	1	8	19	73
65+ years	30	25	12	33	22	29	15	34	11	31	22	36	2	19	36	43

\*Folate intake categories defined by total average folate intake in µg/d.

†Strategies labelled by amount of fortification in µg of folic acid added per 100g of enriched grain product.